Search | Caixin

di ning

Dr Reddy’s Is First Indian Drugmaker Accepted by China Pilot Program

Dr Reddy's Laboratories Ltd. became the first Indian pharmaceutical company to win approval to supply
Exclusive: Embattled Chinese Vaccine-Maker One Step Away From Delisting

The troubled drugmaker embroiled in China’s worst vaccine scandal last summer is one step away from delisting
In Depth: Too Costly and Too Late: Why Curable Liver Disease Is Still Ravaging Rural China

At the foot of a mountain covered in green and surrounded by farmland, Dashuidong village in Central
China Approves New Rheumatoid Arthritis Drug

Another global pharmaceutical company won government approval to sell a drug to sufferers of rheumatoid
In Depth: Why China’s Drug-Review Revamp Is Stalling

Budget constraints and loss of talent are hobbling China’s top drug evaluation agency, fueling industry
In Depth: Domestic Medical-Device Startups Struggling To Cut Through

Domestic startups angling for a piece of China’s high-end medical-device market are struggling to break
Chinese Medical Device Startups Face Tough Market

Domestic startups angling for a piece of China’s booming medical device market are struggling to break
Money-Losing Vaccine Maker Aims to Soothe Skeptics With Hong Kong IPO

Biotech firm CanSino Biologics Inc. will become China’s first money-losing vaccine maker to list in
Social Issues Under Spotlight at China’s ‘Two Sessions’

As thousands of Chinese lawmakers and political advisers descend on Beijing for the country’s biggest
Chinese Biotech Firm Aims to Beat Foreign Rivals on Price With New Cancer Drug

CEO Li Ning told Caixin on Thursday. Merck’s Keytruda goes for about 300,000 yuan ($43,600) per